In a laboratory at the University of Hong Kong, Professor Kwon Sung Chul and his team have engineered a breakthrough that treats genetic disease like a word processor treats a typo—find, select, delete, replace. Their innovation, called RNA Segment Editing (RSE), functions as a "cut-and-patch" tool that precisely repairs faulty genetic messages inside living cells without permanently altering a person's DNA. The discovery, published in Nature Communications, opens a fundamentally new pathway for treating diseases that have long resisted conventional medicine.
To understand why this matters, consider the difference between DNA and RNA. DNA is the permanent blueprint locked away in the nucleus of every cell; RNA is the messenger that reads that blueprint and carries instructions for building proteins—the workhorses that keep us alive. When RNA messages contain errors or toxic segments, cells malfunction, leading to disease. For decades, scientists have struggled with this problem: existing editing tools either destroy the entire RNA message or fix only single characters, leaving researchers unable to surgically remove the specific problem without collateral damage.
The Hong Kong team's solution hinges on an enzyme called Cas13, which acts like molecular scissors targeting RNA rather than DNA. By engineering Cas13 to work with unprecedented precision, they could snip RNA at exact locations. That was the first breakthrough. The second came when they built the RSE platform around this precise cutting capability—creating a system that works like a "find and replace" function for long segments of RNA. The tool locates a faulty section, cuts it out, and patches in a healthy replacement, all within living cells.
The implications are most vivid in Huntington's disease, a neurodegenerative condition caused by a toxic repetitive segment in RNA that causes brain cells to fail. Current experimental treatments often delete the entire RNA message, risking the loss of beneficial protein functions alongside the harmful ones. RSE changes that calculation entirely. It can selectively remove harmful segments while preserving the healthy ones—addressing the root cause without throwing out the baby with the bathwater.
What sets this approach apart is its reversibility and flexibility. Unlike genetic edits that permanently rewrite the code, RSE works more like a conventional medication: it can be stopped at any time, adjusted for individual needs, or fine-tuned as scientists learn more. "Our goal is to create a tool that enables programmable RNA repair without permanently changing a patient's DNA," Professor Kwon explained. "RSE provides a flexible and safe approach that could be tailored to treat neurodegenerative diseases. This opens exciting new possibilities for RNA-based therapies that can be adjusted or reversed simply by stopping the treatment, much like a conventional pill."
The research team has demonstrated that RSE can correct disease-causing messages across multiple neurodegenerative conditions. What began as a solution to a specific molecular challenge may soon expand treatment options for patients living with conditions that, until now, offered few paths forward. In Hong Kong's biomedical research community, this work signals that the era of reversible, targeted genetic therapy may finally be within reach.